Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Hanseong Roh"'
Autor:
Hanbaek Yi, Jeonghwan Youk, Yoojoo Lim, Hanseong Roh, Dongsoo Kyung, Hwang-Phill Kim, Duhee Bang, Bhumsuk Keam, Tae-Min Kim, Miso Kim, Dong-Wan Kim, Tae-You Kim
Publikováno v:
Cancer Research & Treatment; Jul2024, Vol. 56 Issue 3, p765-773, 9p
Autor:
Sheehyun Kim, Yongjun Cha, Yoojoo Lim, Hanseong Roh, Jun‐Kyu Kang, Kyung‐Hun Lee, Min Jung Kim, Ji Won Park, Seung‐Bum Ryoo, Hwang‐Phill Kim, Seung‐Yong Jeong, Kyu Joo Park, Sae‐Won Han, Tae‐You Kim
Publikováno v:
International Journal of Cancer.
Autor:
Sheehyun Kim, Yoojoo Lim, Jun-Kyu Kang, Hwang-Phill Kim, Hanseong Roh, Su Yeon Kim, Dongin Lee, Duhee Bang, Seung-Yong Jeong, Kyu Joo Park, Sae-Won Han, Tae-You Kim
Publikováno v:
Br J Cancer
BACKGROUND: Circulating tumour DNA (ctDNA) has been spotlighted as an attractive biomarker because of its easy accessibility and real-time representation of tumour genetic profile. However, the clinical utility of longitudinal ctDNA monitoring has no
Autor:
Dae-Won Lee, Yoojoo Lim, Hwang-Phill Kim, Su Yeon Kim, Hanseong Roh, Jun-Kyu Kang, Kyung-Hun Lee, Min Jung Kim, Seung-Bum Ryoo, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Sae-Won Han, Tae-You Kim
Publikováno v:
Cancer Research and Treatment.
Autor:
Youngjoo Lee, Nak Jung Kwon, Sung-Ho Goh, Jae Hyun Jeon, Jin Ho Choi, Moon Soo Kim, Hanseong Roh, Geon Kook Lee, Hee Chul Yang, Ji Young Yun, Ji Youn Han, Jong Mog Lee
Publikováno v:
Lung Cancer. 136:15-22
Accumulating evidence reveals the association between the risk of never-smoker lung cancer and family history of cancer. However, the clinicogenomic effect of family history of cancer in never-smoker lung cancer remains unknown.We screened 3,241 lung
Autor:
Yoojoo Lim, Sheehyun Kim, Jun-Kyu Kang, Hwang-Phil Kim, Hanseong Roh, Su Yeon Kim, Dongin Lee, Duhee Bang, Seung-Yong Jeong, Kyu Joo Park, Sae-Won Han, Tae-You Kim
Publikováno v:
Annals of Oncology. 33:S507
Autor:
Dae-Won Lee, Sae-Won Han, Yoojoo Lim, Hwang-Phill Kim, Hanseong Roh, Min Jung Kim, Seung-Bum Ryoo, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Tae-You Kim
Publikováno v:
Cancer Research. 82:5157-5157
Introduction: Regorafenib is a multikinase inhibitor which showed clinical benefit in patients with treatment refractory metastatic colorectal cancer. However, as only a subset of patients derives clinical benefit from regorafenib, it is essential to
Autor:
Yoojoo Lim, Sheehyun Kim, Jun-Kyu Kang, Hwang-Phill Kim, Hanseong Roh, Su Yeon Kim, Dongin Lee, Duhee Bang, Seung-Yong Jeong, Kyu Joo Park, Sae-Won Han, Tae-You Kim
Publikováno v:
Journal of Clinical Oncology. 40:189-189
189 Background: ctDNA is an attractive alternative to tissue for its easy accessibility and real time representation of systemic tumor profile. We explored the utility of ctDNA profiling during the course of mCRC treatment. Methods: Serial blood samp
Autor:
Kyoung Un Park, Hanseong Roh, Hyung Ho Kim, Soo Kyung Nam, Byung Chul Lee, Woo Ho Kim, Jin Haeng Chung, Jin Won Kim, Jiwon Koh, Do Joong Park, Sang Hoon Ahn, Jonghyuk Kim, Hye Seung Lee
Publikováno v:
Genes, Chromosomes and Cancer. 58:12-22
We aimed to determine somatic mutational profiles of stage II/III gastric cancers (GCs) according to their tumor microenvironment immune types (TMITs), which classify cancer based on co-assessment of PD-L1 expression and CD8+ tumor infiltrating lymph
Autor:
Wan Seop Kim, Kyoung-Yeon Kim, Ha Young Park, Jung-Hoon Park, Hye Seung Lee, Hanseong Roh, Seung Eun Lee
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
HER2-positive luminal B breast cancer (BC), a subset of the luminal B subtype, is ER-positive and HER2-positive BC which is approximately 10% of all BC. However, HER2-positive luminal B BC has received less attention and is less represented in previo